Skip to main content
. Author manuscript; available in PMC: 2022 Aug 23.
Published in final edited form as: Nat Med. 2021 Jun 21;27(8):1401–1409. doi: 10.1038/s41591-021-01383-w

Table 1 |.

Bivariate associations of clinical characteristics with C. auris-colonization status at the time of the first survey

Colonized (n = 46) Not colonized (n = 11) OR (95% CI) P value

Length of stay (d) between admission and first swab (M ± IQR) 361 ± 801 571 ± 1,372 1.00 (0.99,1.00) 0.26
Age in years (mean ± s.d.) 59 ± 14 59 ± 14 1.00 (0.95,1.05) 0.89
Female (n (%)) 18 (39) 5 (45) 0.77 (0.20,2.91) 0.74
African American (n (%)) 31 (74) 9 (90) 0.31 (0.066,2.76) 0.42
Mechanical ventilation (n (%)) 23 (50) 0 (0) 23.00 (1.28,413.3) 0.002
Gastrostomy tube (n (%)) 35(78) 3 (27) 9.33 (2.08,41.89) 0.003
Tracheostomy (n (%)) 34 (74) 6 (55) 2.36 (0.61,9.17) 0.27
Urinary catheter (n (%)) 33 (72) 3 (27) 6.77 (1.55,29.56) 0.012
Hospital stay within past 90d (n (%)) 20 (44) 3 (27) 2.13 (0.50,9.11) 0.5
Charlson comorbidity index (M ± IQR) 3 ± 2 3 ± 2 0.91 (0.65,1.28) 0.59
Congestive heart failure (n (%)) 10 (22) 5 (45) 0.33 (0.084,1.32) 0.11
Chronic lung disease (n (%)) 36(78) 6 (55) 3.00 (0.76,11.90) 0.11
Braden scale scorea (mean ± s.d.) 13 ± 2 16 ± 5 0.74 (0.59,0.94) 0.013
History of carbapenemase- producing bacterial colonization or infectionb 31 (67) 6 (55) 1.72 (0.45,6.56) 0.49
Antibacterial receipt in prior 90 d (n (%)) 34 (74) 5 (45) 3.4 (0.88,13.21) 0.030
Antifungal receipt in prior 90 d (n (%)) 5 (11) 0 (0) 3.05 (0.16,59.29) 0.57
a

The Braden Scale for Predicting Pressure Sore Risk assesses a person’s risk of developing a pressure ulcer by examining six criteria: moisture, activity, mobility, nutrition and friction and shear.

b

Screening of facility residents for carbapenemase-producing bacterial colonization was performed routinely. Screening for colonization by other multidrug-resistant organisms was not performed.

CI, confidence interval; IQR, interquartile range; M, median; OR, odds ratio.